Recently released vaccine data indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). When vaccine doses first become available, who should be prioritized?
Recently released vaccine data from Pfizer, Moderna, and AstraZeneca indicate encouraging steps forward in the global fight against coronavirus disease 2019 (COVID-19). But all 3 vaccines are still a long way from becoming readily available to the wider public, prompting the question, who should be prioritized once doses become available?
To provide guidance on this front, the National Institutes of Health (NIH) and CDC requested The National Academies of Science, Engineering, and Medicine (NASEM) to construct a framework assisting US policy makers and global health communities to plan for an equitable allocation of a COVID-19 vaccine.
On this episode of Managed Care Cast, we speak with Jewel Mullen, MD, MPH, the associate dean for health equity and associate professor of population health and internal medicine at the University of Texas at Austin, Dell Medical School. Mullen is the former principal deputy assistant secretary for health in HHS and a member of the National Academies committee which developed the framework for vaccine allocation.
Mullen discusses criteria used to prioritize vaccine recipients, barriers to equitable distribution, and the role of misinformation in the push for an effective COVID-19 vaccine.
Listen above or through one of these podcast services:
Read more:
Pfizer Says Vaccine 90% Effective; Biden Team Announces COVID-19 Transition Panel
Study Backs Decision to Move Forward With Pfizer Vaccine Candidate
Moderna SARS-CoV-2 Vaccine Elicits Response in Older Adults
Dr Maura Abbott: Talk to Your Patients About Their Vaccine Fears
Dr Maura Abbott: COVID-19 Vaccine Development Process Is Safe Despite a Quicker Timeline
Dr Victoria Smith on Experience Taking Part in a COVID-19 Vaccine Trial
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen